0001144204-15-027693.txt : 20150505
0001144204-15-027693.hdr.sgml : 20150505
20150505170648
ACCESSION NUMBER: 0001144204-15-027693
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150501
FILED AS OF DATE: 20150505
DATE AS OF CHANGE: 20150505
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NAVIDEA BIOPHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000810509
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 311080091
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5600 BLAZER PARKWAY
STREET 2: SUITE 200
CITY: DUBLIN
STATE: OH
ZIP: 43017
BUSINESS PHONE: 6147937500
MAIL ADDRESS:
STREET 1: 5600 BLAZER PARKWAY
STREET 2: SUITE 200
CITY: DUBLIN
STATE: OH
ZIP: 43017
FORMER COMPANY:
FORMER CONFORMED NAME: NEOPROBE CORP
DATE OF NAME CHANGE: 19940714
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LARSON BRENT L
CENTRAL INDEX KEY: 0001195766
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35076
FILM NUMBER: 15833928
MAIL ADDRESS:
STREET 1: 425 METRO PLACE NORTH
STREET 2: STE 400
CITY: DUBLIN
STATE: OH
ZIP: 43017
4
1
form474300_20150505050629-.xml
X0306
4
2015-05-01
0
0000810509
NAVIDEA BIOPHARMACEUTICALS, INC.
NAVB
0001195766
LARSON BRENT L
5600 BLAZER PARKWAY, SUITE 200
DUBLIN
OH
US 43017
0
1
0
0
EVP, CFO, Treas and Sec'y
Common Stock
2015-05-01
4
S
0
12500
1.33
D
309737
D
Sales effected pursuant to a 10b5-1 trading plan adopted by Mr. Larson on March 13, 2015
Weighted average of sales prices ranging from $1.31 to $1.35 per share. Mr. Larson undertakes to provide upon request by the Staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
William J. Kelly, attorney-in-fact
2015-05-05